Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches.
about
Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis.Pulsed dye laser as an excellent choice of treatment for lupus tumidus: a prospective study.Expression of interleukin-17 is correlated with interferon-α expression in cutaneous lesions of lupus erythematosus.Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9.Familial cutaneous lupus erythematosus (CLE) in the German shorthaired pointer maps to CFA18, a canine orthologue to human CLECutaneous manifestations of systemic lupus erythematosus.Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patientsPathogenesis of cutaneous lupus erythematosus.Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer.Pathogenesis of cutaneous lupus erythematosus: common and different features in distinct subsets.The pathogenesis of primary cicatricial alopeciasRecent advances in cytokines in cutaneous and systemic lupus erythematosus.Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review.Lupus erythematosus revisited.PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia.Genome-wide association study identifies new susceptibility loci for cutaneous lupus erythematosus.Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupA model of skin inflammation in humans leads to a rapid and reproducible increase in the interferon response signature: a potential translational model for drug development.Interferon-α stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus.The Absent in Melanoma 2-Like Receptor IFN-Inducible Protein 16 as an Inflammasome Regulator in Systemic Lupus Erythematosus: The Dark Side of Sensing Microbes.Type I interferon signature in the initiation of the immune response in vitiligoThe Role of CXCR3 and Its Chemokine Ligands in Skin Disease and Cancer
P2860
Q33877996-3ECF476A-1569-4ED8-A16B-A4A161A74015Q34034899-FB92B473-BE6E-4E39-AE8F-A39AE2F71F9AQ34188885-117B1925-7E3C-46B1-ADEE-E9239DCD9D62Q34420799-F858F69A-B7C5-4E1D-A705-829C5A0370A6Q35592135-DFD75B49-B057-432D-BDF8-2670B0BB2A36Q36134951-E940C502-641C-40E3-B7C9-E80A1CC28917Q36993253-D7B0A89B-6BB1-4763-B086-105335FD6A11Q37168011-38037A1D-1A17-4FED-ACB3-E16D7935B507Q37619948-FE7F99D9-07E3-4AD8-BF3C-79E9E817B37EQ37778642-96C04251-68A7-4809-B29C-695B9319D0B3Q37796446-39BF1B86-35E2-450C-8F0C-92BF61587481Q37902251-0987DAFE-4BD8-433D-A3E0-446F252303D4Q38178160-10AA2072-C570-459D-A675-9BC6E1936E4EQ38659241-2AC484AF-551F-425B-B17B-621490E7031CQ48247479-63FEC783-9B9D-43A6-AC35-632DDA337F8AQ52954693-78D3ECFC-5FA3-415C-B4C1-8FD0F04AD7F1Q53343146-15AF595B-284A-406D-AC66-F4B10378FD66Q53635670-82B77B25-582F-45DE-9B50-D1A13882DC2FQ54362387-E80AF382-683F-425E-8B7E-8877486C05E6Q55436021-4C25790B-5848-4942-8F37-906FCC7019DAQ56996562-89697051-791D-4394-957F-AA77E8182719Q57492052-C27B742E-0394-4CA6-85B8-406B5D15A6A9
P2860
Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Identification of type I inter ...... novel therapeutic approaches.
@ast
Identification of type I inter ...... novel therapeutic approaches.
@en
type
label
Identification of type I inter ...... novel therapeutic approaches.
@ast
Identification of type I inter ...... novel therapeutic approaches.
@en
prefLabel
Identification of type I inter ...... novel therapeutic approaches.
@ast
Identification of type I inter ...... novel therapeutic approaches.
@en
P2860
P1476
Identification of type I inter ...... r novel therapeutic approaches
@en
P2093
Thomas Tüting
P2860
P304
P356
10.1111/J.1600-0625.2007.00556.X
P50
P577
2007-05-01T00:00:00Z